Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates
FATE THERAPEUTICS INC (FATE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be fa
How this was made
The 30-second read
Why it matters
The disclosed data represent the first public release of Phase 1/2 outcomes and IND clearance, providing fresh material for valuation.
Market read
First‑time disclosure of pivotal trial data and regulatory progress; likely to move the stock.
What to watch
Cash runway extends only to mid‑2028; future financing needs could pressure the stock.
Fate Therapeutics reported a third-quarter 2026 net loss of $30.7 million, ended the quarter with $139.1 million in cash, cash equivalents, and investments, and extended its expected cash runway to mid-2028 with a newly awarded $15.0 million CIRM grant.
The company reduced its quarterly net loss versus the third quarter of 2025, lowered nine-month operating expenses, and reported an expected cash runway to mid-2028. Operationally, RECLAIM-LN enrollment is open across 17 active sites and FT839 has entered site activation for COMPLETE, although the clinical data remain preliminary and are based on small patient cohorts.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Collaboration revenue, three months ended September 30, 2026GAAP | $ — (in thousands) | – | – |
| Research and development expenses, three months ended September 30, 2026GAAP | $24.21M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $8.03M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $32.25M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$32.25M | – | – |
| Interest income, three months ended September 30, 2026GAAP | $1.41M | – | – |
| Change in fair value of stock price appreciation milestones, three months ended September 30, 2026GAAP | $151K | – | – |
| Other income, three months ended September 30, 2026GAAP | $ — (in thousands) | – | – |
| Total other income, net, three months ended September 30, 2026GAAP | $1.56M | – | – |
| Net loss, three months ended September 30, 2026GAAP | −$30.69M | – | – |
| Net loss per common share, basic and diluted, three months ended September 30, 2026GAAP | $ (0.25) | – | – |
| Weighted-average common shares used to compute basic and diluted net loss per share, three months ended September 30, 2026GAAP | 123,656,809 | – | – |
| Comprehensive loss, three months ended September 30, 2026GAAP | −$30.73M | – | – |
| Collaboration revenue, nine months ended September 30, 2026GAAP | $3.38M | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $73.31M | – | $9.1 million, 11% reduction |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $26.46M | – | $9.4 million, 26% reduction |
| Total operating expenses, nine months ended September 30, 2026GAAP | $99.76M | – | decreased by $18.5 million |
| Loss from operations, nine months ended September 30, 2026GAAP | −$96.38M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$92.06M | – | – |
| Net loss per common share, basic and diluted, nine months ended September 30, 2026GAAP | $ (0.76) | – | – |
| Cash, cash equivalents, and investments, as of September 30, 2026other | $139.1M | a quarterly decrease of $14.7 million | – |
| Cash and cash equivalents, as of September 30, 2026GAAP | $43.94M | – | – |
| Short-term investments, as of September 30, 2026GAAP | $95.19M | – | – |
| Total assets, as of September 30, 2026GAAP | $238.3M | – | – |
| Accounts payable and accrued expenses, as of September 30, 2026GAAP | $18.07M | – | – |
| CIRM award liability, as of September 30, 2026GAAP | $ 9,508 (in thousands), current portion; $ 2,377 (in thousands), net of current portion | – | – |
| Operating lease liability, as of September 30, 2026GAAP | $ 5,110 (in thousands), current portion; $ 69,383 (in thousands), net of current portion | – | – |
| Stockholders' equity, as of September 30, 2026GAAP | $133.0M | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
mid-2028 outlook
- NoteCash, cash equivalents, and investments of $139.1 million, along with the newly awarded $15.0 million CIRM grant, extends the cash runway to mid-2028.
What drove it
- RECLAIM-LN enrollment is open across 17 active sites; the first patient was treated in an outpatient setting in August.
- The RECLAIM-LN Phase 2 potentially registrational trial is expected to enroll approximately 53 patients and uses complete renal response at Week 26 as its primary endpoint.
- In active lupus nephritis patients treated with FT819 and bendamustine conditioning, patients with Month 6 follow-up (n=2) achieved a CRR or primary efficacy renal response, and mean UPCr decreased by approximately 50% from baseline.
- The FDA cleared the FT839 IND application in July, and the company has activated multiple sites for the COMPLETE Phase 1/2 basket trial.
- The company received a $15.0 million CIRM CLIN2 grant to support RECLAIM-LN.
Concerns
- Collaboration revenue was $ — (in thousands) for the third quarter of 2026, compared with $ 1,741 (in thousands) for the third quarter of 2025.
- Clinical efficacy observations remain preliminary, including the lupus nephritis Month 6 cohort of n=2.
- The company states that preliminary clinical results may change as additional patients are treated and additional data become available and may not predict results in larger or potentially registrational trials.
- The cash position excludes cash from the recently awarded $15.0 million CIRM grant, and the company identifies risks to receiving or utilizing CIRM grant funding in the anticipated timeframe or manner.
- FT839 patient dosing is expected by year-end, and timing depends on site activation, screening, enrollment, dosing, manufacturing, release, and supply.
What to watch
- Enrollment progress and clinical data from the approximately 53-patient RECLAIM-LN trial.
- FT819 updates at ACR Convergence 2026, including administration without conditioning chemotherapy, a biomarker association with improvement in fatigue, and outpatient administration progress.
- The expected dosing of patients in COMPLETE by year-end 2026, including in rheumatoid arthritis.
- New extrarenal SLE data and FT839 preclinical and trial-design updates planned for ACR Convergence 2026.
- Continued enrollment and preliminary anti-tumor activity evidence in the FT836 solid tumor basket study.
Balance sheet and cash flow
- Cash, cash equivalents, and investments as of September 30, 2026, were $139.1 million, a quarterly decrease of $14.7 million.
- Cash position does not include cash from the recently awarded CIRM grant of $15.0 million.
- Cash and cash equivalents were $ 43,942 (in thousands) as of September 30, 2026.
- Short-term investments were $ 95,190 (in thousands) as of September 30, 2026.
- No cash flow statement, operating cash flow, free cash flow, or debt balance was reported in the filing.
Analysis
Fate Therapeutics reported a third-quarter GAAP net loss of $ (30,687) (in thousands), or $ (0.25) per common share, compared with $ (32,250) (in thousands), or $ (0.27) per common share, in the third quarter of 2025. Collaboration revenue was $ — (in thousands), compared with $ 1,741 (in thousands) a year earlier. Total operating expenses were $ 32,247 (in thousands), comprising $ 24,215 (in thousands) of research and development expense and $ 8,032 (in thousands) of general and administrative expense.
Cost discipline is evident in the nine-month comparison. Total operating expenses for the nine months ended September 30, 2026 were $ 99,762 (in thousands), compared with $ 118,260 (in thousands) in the prior-year period, a decrease stated as $18.5 million. The company attributed this to a $9.1 million, 11% reduction in research and development expenses and a $9.4 million, 26% reduction in general and administrative expenses. Nine-month net loss was $ (92,059) (in thousands), compared with $ (103,941) (in thousands).
Liquidity remains the central financial support for the clinical pipeline. Cash, cash equivalents, and investments were $139.1 million as of September 30, 2026, reflecting a quarterly decrease of $14.7 million. The company said this balance, together with the newly awarded $15.0 million CIRM grant, extends its cash runway to mid-2028. The cash position reported does not include cash from that grant. No capital returns, operating cash flow, free cash flow, or debt balance were reported.
The principal operating focus is FT819 in autoimmune disease. RECLAIM-LN is open at 17 active sites and is expected to enroll approximately 53 patients. In the bendamustine-conditioned active lupus nephritis cohort, the company reported that Month 6 patients with follow-up (n=2) achieved a CRR or primary efficacy renal response, while mean UPCr decreased by approximately 50% from baseline. Safety data across 29 autoimmune patients showed no dose-limiting toxicities, ICANS, GvHD, IEC-HS, or deaths, although Grade 1–2 CRS occurred in 5 patients (17.2%), Grade ≥3 infections occurred in 2 patients (6.9%), and Grade ≥3 cytopenias occurred in 6 patients (20.7%).
FT839 broadens the near-term catalyst set following FDA clearance of its IND application in July. Multiple COMPLETE trial sites have been activated, and the company expects to dose patients by year-end, including in rheumatoid arthritis. The key execution tests are RECLAIM-LN enrollment and durability data, the scale-up from small early FT819 cohorts, FT839 dosing progress, and preservation of the stated mid-2028 cash runway as clinical activity expands.
Management, verbatim
The third quarter was defined by steady execution across our portfolio, bringing us closer to our goal of delivering off-the-shelf, master cell bank derived cell therapies to the patients who need them most.
Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics
Momentum continues to build for RECLAIM-LN, and the updated Phase 1 data presented at ASN Kidney Week further supports the Phase 2 study design, including updated safety and efficacy data that reinforces the unique and encouraging product profile of FT819 in lupus.
Bob Valamehr, Ph.D., MBA, President and Chief Executive Officer of Fate Therapeutics
Not in the filing
stated, not guessed- Total revenue was not reported as a separate line item; only collaboration revenue was reported.
- Gross profit, gross margin, operating margin, tax expense, and tax rate were not reported.
- Non-GAAP financial measures, including non-GAAP net income or loss, non-GAAP EPS, and adjusted EBITDA, were not reported.
- Prior-quarter financial comparisons for the reported income-statement metrics were not reported.
- A cash flow statement, operating cash flow, capital expenditures, and free cash flow were not reported.
- Debt was not reported.
- Share repurchases, dividends, and other capital-return activity were not reported.
- Revenue segments were not reported.
- Prior-period outlook was not provided, so comparison with prior guidance is unavailable.
- A specific operating-expense guidance figure was not provided.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
Fate Therapeutics filed a Form 8‑K reporting Q3 2026 results and updates on its autoimmune CAR‑T pipeline.
Ticker impact
SEC 8‑K reports Phase 1/2 data for FT819 in lupus nephritis and FT839 IND clearance, plus $15 M CIRM grant and $139 M cash runway.
upward pressure as market prices in encouraging safety and efficacy signals.
First disclosure of Phase 1/2 results and regulatory IND clearance; material for a clinical‑stage biotech.
Market effects
Strengthens outlook for iPSC‑derived CAR‑T therapies and may lift peer biotech valuations.
Positive for US biotech sector; limited broader market effect.
Limited to biotech investors, no macro impact.
Counterpoint
Trial size is small; efficacy signals are early and may not translate to later phases.
Key entities
- companyFate Therapeutics Inc.
Clinical‑stage biotech developing iPSC‑derived CAR‑T therapies.
- productFT819
iPSC‑derived CAR‑T candidate for lupus nephritis.
- productFT839
Dual CD19/CD38 CAR‑T candidate cleared for IND.
